Retrospective Comparison of Commercially Available Automated Insulin Delivery With Open-Source Automated Insulin Delivery Systems in Type 1 Diabetes
Authors' conclusion
In conclusion, both groups were able to achieve satisfactory glycemic outcomes independent of age, gender, and diabetes duration. However, the PWT1D using OS-AID systems attained an even better glycemic control with no clinical safety concerns.
Study context
- Population
- People with T1D using MiniMed 670G or OS-AID routinely for 3 to 6 months, February 18, 2020 to January 15, 2023, Austria
- Participants
- 144 people
- Exposure
- Open-source automated insulin delivery (AID) vs MiniMed 670G
- OS-AIDn = 28
- 670Gn = 116reference
- Outcome
- Quality of glycemic control
Methodological detailsdescriptive analysis, no statistical tests
- Descriptive analysis
- No statistical tests
Main finding
As reported in the abstract
Time in range (TIR) 70-180 mg/dL
Observational data: associations, not effects.
Further findings
TAR 181-250 mg/dL
TAR >250 mg/dL
HbA1c
Median glucose
Safety
TBR 54-69 mg/dL
TBR <54 mg/dL
Time below range (TBR) <54 mg/dL
- Comparable in both groups
Original publication
Retrospective Comparison of Commercially Available Automated Insulin Delivery With Open-Source Automated Insulin Delivery Systems in Type 1 Diabetes. J Diabetes Sci Technol. Published 16 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →